Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance

Tarek Mazzawi¹,² and Magdy El-Salhy¹,²,³

¹Division of Gastroenterology, Department of Clinical Medicine, University of Bergen, Bergen 5021, Norway; ²National Centre for Functional Gastrointestinal Disorders, Division of Gastroenterology, Department of Medicine, Haukeland University Hospital—Helse Bergen, Bergen 5021, Norway; ³Division of Gastroenterology, Department of Medicine, Stord Hospital—Helse Fonna, Stord 5416, Norway

Corresponding author: Tarek Mazzawi. Email: tarek.mazzawi@med.uib.no, tarek.mazzawi@gmail.com

Impact statement
Several contributing factors to the symptomology of irritable bowel syndrome (IBS) have been identified, such as abnormal densities of enteroendocrine cells and diet; however, the interactions between these factors have not been studied yet. The current study aims at exploring the dynamic changes between these two factors by studying the effect of using low fermentable oligo-, di-, monosaccharides and polyol (FODMAP) diet (known to improve IBS symptoms) through dietary guidance on the enteroendocrine cell densities in the duodenum. The findings showed that the densities of different enteroendocrine cells in the duodenum were abnormal before the patients received dietary guidance and tend to change/normalize after receiving guidance, which may have contributed in improving the symptoms of IBS. These findings highlight the importance of enteroendocrine cells in IBS pathophysiology and the mechanism behind the positive effect of low FODMAP dietary guidance in improving IBS symptoms and its usage as first step in the line of IBS management.

Abstract
The densities of enteroendocrine cells are abnormal in patients with irritable bowel syndrome (IBS); however, they tend to change toward normal levels in stomach, ileum, and colon following dietary guidance. The aim was to identify the types of duodenal enteroendocrine cells affected after receiving dietary guidance in the same group of patients with IBS. Fourteen patients with IBS and 14 control subjects were included. The patients received three sessions of dietary guidance. Both groups underwent gastroscopies at baseline, and again for the patients after 3–9 months (median, four months) from receiving dietary guidance. Tissue biopsies were collected from the descending part of the duodenum and were immunostained for all the types of enteroendocrine cells and were then quantified by using computerized image analysis. Using the Kruskal–Wallis non-parametric test with Dunn’s test as a post-test, the results showed a significant difference in the secretin cell densities between control subjects and patients with IBS prior to and following dietary guidance (P = 0.0001 and 0.011, respectively). The corresponding P values for cholecystokinin (CCK) cell densities were 0.03 and 0.42, respectively; gastric inhibitory peptide (GIP) cell densities were 0.06 and 0.43, respectively; serotonin cell densities were <0.0001 and 0.002, respectively; and for somatostatin cell densities were <0.0001 and 0.052, respectively. The Paired t-test showed a significant difference only in the serotonin (P = 0.03) and somatostatin (P < 0.0001) cell densities between IBS patients prior to and following dietary guidance. The changes in the cell densities of secretin, CCK, and GIP were not significant between IBS patients prior to and following dietary guidance. In conclusion, the densities of several duodenal enteroendocrine cells in IBS patients changed toward the values measured in control subjects following dietary guidance. The changes in serotonin and somatostatin cell densities may have contributed to the improvements in IBS symptoms, particularly pain and diarrhea.

Keywords: Computerized image analysis, diet, duodenum, enteroendocrine cells, irritable bowel syndrome, immunohistochemistry

Experimental Biology and Medicine 2017; 242: 1355–1362. DOI: 10.1177/1535370217699537

Introduction
Irritable bowel syndrome (IBS) is a chronic disorder of the gastrointestinal (GI) tract characterized by abdominal pain or discomfort, bloating, and altered bowel movements.¹ The etiology of IBS is not known, but several factors appear to contribute to its pathophysiology, including diet, hereditary factors, low-grade inflammation, microbiota, and abnormal enteroendocrine cells.²,³ Most patients with IBS believe that certain foodstuffs trigger their IBS symptoms,⁴–⁶ mainly those that are rich with fermentable oligo-, di-, monosaccharides and polyols (FODMAPs), and insoluble fibers.⁷–¹¹ Dietary guidance
promoting a low-FODMAP diet along with altering the proportions of carbohydrates, protein, and fat in the diet has shown to alleviate IBS symptoms and improve the patients' quality of life (QOL).8,12

Enteroendocrine cells play a crucial and major role in regulating several GI functions, including visceral sensitivity, secretion, absorption, motility, proliferation of epithelial and mesenchymal cells, local immune defense, and appetite.13 Such regulation occurs through the exocytosis of hormones at the basolateral surface of the enteroendocrine cells.14–19 The enteroendocrine cells are abnormal throughout the GI tract in IBS patients20–26 and previous studies have shown that dietary guidance changes the enteroendocrine cell densities toward the values measured in control subjects in the stomach, ileum, and colon27–32 in the same group of IBS patients in the current study. Moreover, dietary guidance has normalized the densities of the duodenal chromogranin A immunoreactive cells,31 which are considered as general marker for enteroendocrine cells.33–35 However, it is not clarified which types of enteroendocrine cells were affected. Therefore, the current study was undertaken to determine which enteroendocrine cell types are affected in IBS patients after they receive dietary guidance.

Material and methods

Study design

A total of 46 patients (35 females and 11 males with an age range 18–69 years [mean 35 years]) who were referred to gastroenterology outpatient clinic, Stord Hospital, Stord, Norway, and fulfilled Rome-III criteria for the diagnosis of IBS were included in this study. The patients have been subjected to a physical examination, blood tests (to exclude any infections, inflammations, and other organic/systemic diseases), and then received three individual sessions of dietary guidance, each for 45 min, at intervals of minimum two weeks, provided by certified nurse specialized in diet and IBS (Figure 1). The patients were also scheduled for a gastroscopy examination before the sessions of dietary guidance and again after 3–9 months (median of four months) from the last session. Fourteen subjects (nine females and five males), age range 26–70 years (mean 54 years), with no previous history of IBS were included as a control group. The inclusion and exclusion criteria for the patients and controls in the current study were previously described.31

The Regional Committees for Medical and Health Research Ethics of western Norway, Bergen, Norway approved the study (number 2010/2650-2). The current study was performed in accordance with the Declaration of Helsinki. All of the participants consented (orally and in written forms) to participate in this study.

Sessions of dietary guidance

The sessions of dietary guidance were previously described in details.32 In brief, during the first session, the patients received information about IBS to enhance their general knowledge concerning IBS. The patients were informed about the dietary items that worsen IBS symptoms and received a list with the dietary items that are high and low in FODMAPs (Table 1). The patients were told to alternately consume food items that were rich and then poor in proteins, fats, and carbohydrates, for approximately equal number of days for a period of two weeks. Meanwhile, the patients were supposed to write down in a daily diary the time and type of food and fluids they consumed, any associated symptoms, and the type and frequency of their abdominal discomfort and bowel movements. The second session focused on reviewing the diaries and recognizing the foods that were considered as symptom triggers, which enabled the patients to modify the amount of consumed proteins, fats, and carbohydrates and reduce the consumption of insoluble fiber and FODMAPs. The usage of antibiotics, probiotics, or proton pump inhibitors was not allowed at least one week before or during the study. During the last session, the patients provided their personal comments and experiences of the dietary guidance.
Table 1 Advisory list of foods for patients with IBS

| High in FODMAPs (not allowed) | Low in FODMAPs (allowed) |
|------------------------------|--------------------------|
| Wheat                        | Spelt and spelt products |
| Pasta                        | Meat                     |
| Maize                        | Fish                     |
| Mushrooms                    | Chicken                  |
| Onion                        | Fat and oil              |
| Garlic                       | Rice                     |
| Beans                        | Potato                   |
| Peas                         | Carrots                  |
| Cauliflower                  | Tomato                   |
| Cabbage                      | Apples and pears (peeled)|
| Broccoli                     | Citrus fruits            |
| Grapes                       | Strawberries and blueberries|
| Mango                        | Lactose-free milk        |
| Artificial sweeteners        | Lactose-free dairy products|
| Carbonated drinks            | Chocolate                |
|                              | Coffee and tea           |
|                              | Alcohol                  |

FODMAP: fermentable oligo-, di-, monosaccharides and polyol; IBS: irritable bowel syndrome.

Gastroscopy and immunohistochemistry

The participants of both groups fasted overnight prior to undergoing a gastroscopy. During the gastroscopy, four tissue biopsies were collected from the descending part of the duodenum, distal to major duodenal papilla. The preparation of the slides was previously described in details. The sections were stained with hematoxylin (Harris Hematoxylin satin [Ortho], Ref.: RBA-4213-00A, Cellpath Ltd, Newtown, Powys, UK)-eosin (Eosin Y, Ref: 1.15935.0100, CAS.no: 17372-87-1, Merck KGaA, 64271 Darmstadt, Germany) and immunostained with an ultraView Universal DAB Detection Kit (cat.no. 760-500, Ventana Medical Systems, Basel, Switzerland). The sections were then incubated with primary antibodies, diluted according to the suppliers’ recommendations as previously described, for the detection of secretin (code sc-20938, Santa Cruz Biotechnology, Santa Cruz, CA, United States), cholecystokinin (CCK; code A0568, Dako, Glostrup, Denmark), gastric inhibitory peptide (GIP; code no. sc-57162, Santa Cruz Biotechnology), somatostatin (code AU566, Dako), and serotonin (code R87104 B56-1, Dako).

Computerized image analysis

Image analysis was performed using ×40 objective on the light microscope and a computer software (Cell^B, Olympus, Tokyo, Japan). The number of immunoreactive enteroendocrine cells was quantified in 10 randomly chosen fields with epithelial cell area measured at 0.09 mm² per slide. The density of each enteroendocrine cell type was expressed as the number of cells/mm² of epithelium. By keeping the identity of the slides concealed, the quantifications of all the slides were conducted by the same person (TM).

Statistical analysis

Fisher’s exact test is used for sex comparisons between control subjects and patients, while the Mann–Whitney U test is used to compare between the ages of both groups. The Kruskal–Wallis non-parametric test with Dunn’s test as a post-test is used to compare between the enteroendocrine densities of the control subjects and patients before dietary guidance and also between the enteroendocrine densities of control subjects and patients after dietary guidance. The paired t-test is used to compare the enteroendocrine densities of the patients between before and after receiving dietary guidance. The data are presented as mean±SEM values. P < 0.05 are considered to be statistically significant.

Results

Patients and control subjects

The study initially included 46 patients who were planned to receive three sessions of dietary guidance. However, many of these patients were excluded/dropped out of the study due to different reasons, including newly diagnosed with celiac disease (following first gastroscopy) or lupus, cooperation problems, non-compliance, pregnancy, moving abroad, being treated with antibiotics because of gastroenteritis or withdrawing their consent, as shown in the
flowchart (Figure 1). These dropouts meant that only 14 patients (nine females and five males) with an age range 21–44 years (mean 33 years) completed the study. There was a significant difference between the patient and control groups in age ($P = 0.0002$) but not in sex ($P = 1$).

**Changes in IBS symptoms and QOL**

The changes in symptoms and QOL in IBS patients in the current study have been described previously.$^{12}$ Briefly, IBS symptoms as assessed by Birmingham questionnaire showed significant improvements particularly in the domains of pain ($P < 0.001$) and diarrhea ($P < 0.05$) but not in constipation, after receiving dietary guidance. The total scores for QOL as assessed by the IBS-QOL and SF-NDI showed significant improvements in the QOL in IBS patients after they have received dietary guidance ($P = 0.003$ and $0.002$, respectively).$^{12}$

**Dietary assessment**

The changes in diet implemented in the present study have been described previously.$^{12}$ In brief, the patients’ daily total consumption of FODMAPs decreased significantly between before (16.2 ± 5.3 g) and after (9.2 ± 3.2 g) receiving dietary guidance ($P = 0.02$). However, the daily consumption of fiber did not significantly change (27.4 ± 2.5 g versus 23.1 ± 2.2 g, $P = 0.09$).$^{12}$

**Gastroscopy and immunohistochemistry**

The gastroscopies showed that the duodenal mucosa was macroscopically normal in both patients and control subjects. Histopathological examinations of the duodenal biopsies from patients and control subjects were also normal. Immunoreactive enteroendocrine cells were found among the epithelial cells both in patients and control subjects; they were either basket- or flask-shaped and sometimes with a long basal cytoplasmic process.

**Computerized image analysis**

The immunoreactive cell densities in the control subjects and IBS patients are summarized in Table 2 and illustrated for secretin, CCK, GIP, and serotonin in Figures 2 to 5, respectively, and for somatostatin in Figures 6 and 7. The cell densities of secretin, CCK, serotonin, and somatostatin in the duodenum of IBS patients before receiving dietary guidance were significantly lower ($P = 0.0001$, $0.03$, $<0.0001$, and $<0.0001$, respectively) than control

| Table 2 Densities of immunoreactive enteroendocrine cells in the duodenum of control subjects and of IBS patients before and after receiving dietary guidance |
|---|
| **Endocrine cell density (cells/mm²)** |
| **Hormone** | **Control** | **Before guidance** | **After guidance** | **p**<sup>a</sup> | **p**<sup>b</sup> | **p**<sup>c</sup> |
| Secretin | 76.9 ± 3.8 | 54.4 ± 2.1 | 61.1 ± 3.4 | 0.0001<sup>a</sup> | 0.011<sup>b</sup> | 0.05 |
| CCK | 80.7 ± 4.0 | 64.1 ± 4.2 | 77.8 ± 8.2 | 0.03<sup>b</sup> | 0.42 | 0.21 |
| GIP | 54.3 ± 4.9 | 39.4 ± 2.7 | 45.0 ± 3.9 | 0.06 | 0.43 | 0.09 |
| Serotonin | 76.1 ± 11.9 | 6.8 ± 1.8 | 20.6 ± 6.0 | <0.0001<sup>c</sup> | 0.002<sup>d</sup> | 0.03<sup>b</sup> |
| Somatostatin | 43.1 ± 5.2 | 10.7 ± 1.5 | 24.4 ± 2.4 | <0.0001<sup>c</sup> | 0.052 | <0.0001<sup>c</sup> |

CCK: cholecystokinin; GIP: gastric inhibitory peptide; IBS: irritable bowel syndrome.

Data are mean ± SEM values. *P*: control versus before guidance, **P**: control versus after guidance, ***P**: before versus after guidance.

<sup>a</sup>$P < 0.001$.

<sup>b</sup>$P < 0.05$.

<sup>c</sup>$P < 0.0001$.

<sup>d</sup>$P < 0.01$. 

![Secretin cell densities in the duodenum of IBS patients before and after receiving dietary guidance. The dashed lines labeled ‘a’ and ‘c’ indicate the upper and lower limits of the 95% confidence interval of the secretin cell density in control subjects, respectively, while line ‘b’ indicates the mean density. IBS: irritable bowel syndrome](image1)

![CCK cell densities in the duodenum of IBS patients before and after receiving dietary guidance. The dashed lines labeled ‘a’ and ‘c’ indicate the upper and lower limits of the 95% confidence interval of the CCK cell density in control subjects, respectively, while line ‘b’ indicates the mean density. CCK: cholecystokinin; IBS: irritable bowel syndrome](image2)
subjects but not for GIP ($P = 0.06$). Only secretin and serotonin cell densities in the duodenum of IBS patients showed significant difference after receiving dietary guidance ($P = 0.011$ and $0.002$, respectively) compared to control subjects. By comparing the cell densities in the duodenum of IBS patients before and after receiving dietary guidance, secretin cell densities increased marginally ($P = 0.05$), while the cell densities of CCK and GIP did not show any significant change ($P = 0.21$ and $0.096$, respectively) and the cell densities of serotonin and somatostatin increased significantly ($P = 0.03$ and $<0.0001$, respectively) after the patients had received dietary guidance.

**Discussion**

This study was characterized by a high dropout rate, which is consistent with previous studies involving IBS patients. The dropout rate was 72%, which could be due to the demanding study design that required the patients to undergo two invasive procedures...
lates the homeostasis of body water,52,53 and inhibits gastric
secretion.62,63 The cell densities of secretin, CCK, and GIP cells (though not
significant). The finding of the present study showed that these changes occurred due to the significant changes
in the duodenal serotonin and somatostatin cells and also changes in secretin, CCK, and GIP cells (though not
significant).

Secretin stimulates pancreatic exocrine secretion,51 regulates the homeostasis of body water,52,53 and inhibits gastric
emptying and intestinal motility.54,55 CCK delays gastric emptying,56 stimulates gallbladder contraction,57,58 results in the release of pancreatic enzymes,59,60 and suppresses food intake.56,59

Since GIP belongs to the incretins family,61 it increases insulin release from the pancreas61,62 and inhibits gastric acid secretion.62,63 The cell densities of secretin and CCK in the duodenum were significantly lower in our IBS patients while consuming the standard Norwegian diet and before receiving dietary guidance than in our control subjects, which is in accordance with the previous findings.26,45 Serotonin modulates the visceral sensitivity and conveys sensation from the GI tract to the central nervous system by activating Meissner’s plexus (submucosal sensory branch).20,64,65 In addition, serotonin stimulates the intestinal motility and accelerates the intestinal transit.65–67 Somatostatin inhibits intestinal contractions as well as gut excocrine and neuroendocrine secretion.13,68 The density of somatostatin cells in the duodenum was previously found to be lower in IBS patients than in control subjects.26,45 After the IBS patients in the current study received dietary guidance, the densities of secretin, CCK, and GIP cells increased toward the values measured in control subjects, but this increase was insignificant between before and after receiving dietary guidance. On the other hand, serotonin and somatostatin cell densities increased significantly toward the values measured in control subjects. The insignificant changes in secretin and CCK cell densities could be secondary to the significant increase in somatostatin cell density, since both secretin69,70 and CCK70 are inhibited by somatostatin. It is possible to stipulate that the improvement observed in IBS symptoms and as assessed by the Birmingham questionnaire, particularly in the pain and diarrhea domains12 after receiving dietary guidance may be ascribed to the significant changes in the cell densities of serotonin and somatostatin following dietary guidance.

The release of GI hormones is stimulated by food intake and depends on the meal composition, that is the proportions of carbohydrates, proteins, and fats. CCK release into the bloodstream is triggered by the consumption of a fat-rich meal,71 while GIP is released after consuming carbohydrate- and fat-rich meals.72,73 The main trigger for enteroendocrine cells is the GI luminal content, especially the nutrients.13,74 Stem cells differentiate rapidly (within 2–6 days) into mature enteroendocrine cells.75,76 The densities of duodenal stem cells, expressing Musashi and endocrine cell progenitor Neurogenin 3 proteins were lower in IBS patients than in healthy control subjects.45 The interactions between food and enteroendocrine cells are dynamic.68 The changes in the densities of duodenal enteroendocrine cells may be caused by changes in clonogenic factors and/or the differentiation of stem cells.

Conclusion

The current study is the first to show that changing the diet can alter the densities of enteroendocrine cells in the duodenum, similarly to the diet-induced changes in the stomach,27–29 small intestine,31,32 and large intestine.28,30 The changes in the different enteroendocrine cell densities identified herein may have contributed to the previously reported improvement in IBS symptoms and the QOL of these IBS patients.12 The results of the current study shed some light on the involvement of the enteroendocrine cells in the pathophysiology of IBS.

Authors’ contributions: TM planned the study, conducted the computerized image analysis, analyzed the results, and wrote the first draft of the manuscript. ME-S planned the study, recruited patients and control subjects, conducted gastroscopies, contributed to the data analysis, and commented on the manuscript.

ACKNOWLEDGEMENTS

This study was financially supported by a grant from Helse Fonna (project no.: 40415).

DECLARATION OF CONFLICTING INTERESTS

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. El-Salhy M, Gundersen D, Hatiabakk KG, Hausken T. Irritable bowel syn-
drome. New York, NY: Nova Science Publisher, 2012.
2. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012; 18:5151–63
3. El-Salhy M. Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol 2015; 21:7621–36
4. Simren M, Mansson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Björnsson ES. Food-related gastrointestinal symptoms in the irritable bowel syndrome. *Digestion* 2001;63:108–15.

5. Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome—etiology, prevalence and consequences. *Eur J Clin Nutr* 2006;60:667–72.

6. El-Salhy M, Gundersen D. Diet in irritable bowel syndrome. *Nutr J* 2015;14:36.

El-Salhy M, Ostgaard H, Gundersen D, Hatlebakk JG, Hausken T. The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). *Int J Mol Med* 2012;29:723–31.

Ostgaard H, Hausken T, Gundersen D, El-Salhy M. Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. *Mol Med Rep* 2012;5:1382–90.

Biesiekierski JR, Rosella O, Rose R, Liels K, Barrett JS, Shepherd SJ, Gibson PR, Muir JG. Quantification of fructans, galacto-oligosaccharides and other short-chain carbohydrates in processed grains and cereals. *J Hum Nutr Diet* 2011;24:154–76.

Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in patients with irritable bowel syndrome. *Int J Clin Nutr* 2015;69:519–24.

Mazzawi T, Hausken T, Gundersen D, El-Salhy M. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. *Eur J Clin Nutr* 2016;70:175–81.

Mazzawi T, El-Salhy M. Changes in small intestinal chromogranin A-immunoreactive cell densities in patients with irritable bowel syndrome after receiving dietary guidance. *Int J Mol Med* 2016;37:1247–53.

Mazzawi T, El-Salhy M. Dietary guidance and ileal enteroendocrine cells in patients with irritable bowel syndrome. *Exp Ther Med* 2016;12:1398–1404.

Taugnet L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. *N Engl J Med* 2003;348:1134–49.

Wiedemann B, Huttner WB. Synaptophysin and chromogranins/secretogranins—widest constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. *Virchows Arch B Cell Pathol* 1989;58:95–121.

Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. *Endocr Rev* 1991;12:181–7.

Roalf AK, Roberts LM, Wilson S. Evaluation of the Birmingham IBS symptom questionnaire. *BMJ Gastroenterol* 2008;8:30.

Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. *Dig Dis Sci* 1998;43:400–11.

Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, Jia H, Bangdiwala SI. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. *Am J Gastroenterol* 1995;90:999–1007.

Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. *Aliment Pharmacol Ther* 2001;15:207–16.

Arslan G, Lind R, Olafsson S, Flovaag E, Berstad A. Quality of life in patients with subjective food hypersensitivity: applicability of the 10-item short form of the Nepean Dyspepsia Index. *Dig Dis Sci* 2004;49:680–7.
